Advertisement

Strahlentherapie und Onkologie

, Volume 194, Issue 4, pp 363–364 | Cite as

Correction to: Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer

  • Olarn Roengvoraphoj
  • Cherylina Wijaya
  • Chukwuka Eze
  • Minglun Li
  • Maurice Dantes
  • Julian Taugner
  • Amanda Tufman
  • Rudolf Maria Huber
  • Claus Belka
  • Farkhad Manapov
Correction
  • 156 Downloads

Correction to:

Strahlenther Onkol 2017

 https://doi.org/10.1007/s00066-017-1229-3

Unfortunately, the structure of Table 4 was incorrect.

The corrected version of Table 4 can be found below.
Table 4

A summary of clinical trials showing correlation between PET/CT and overall survival in patients with NSCLC

Study

Patient no.

NSCLC stage

Pre-treatment PET/CT

Mid-treatment PET/CT

Post-treatment PET/CT

Endpoint

Machtay et al. (2013) [9]

250

Inoperable stage IIB/III

SUV peak

Not performed

SUV peak

2-Year OS post-treatment SUVpeak > 5

38% vs. 53% Observation arm (p = 0.001)

Usmanij et al. (2013)[10]

28

Inoperable stage III

TLG

Not performed

TLG

Delta TLG decrease of 38% was associated with prolonged PFS

Van Elmpt et al. (2012) [11]

34

Stage II–IV

SUVmean, SUVmax

SUVmean, SUVmax

Not performed

For patients with a decrease in SUV >15%, 2‑year OS was 92%, compared with a median OS of 19 months, and a 33% 2‑year OS, respectively, for the patients with a decrease in mean SUV of less than 15%

Ohri et al. (2015) [24]

214

Inoperable stage IIB/III

MTV

Not performed

Not performed

Median OS for patients with MV < 95.4 cm3 23.6 vs. 13.4 months (p < 0.001)

Markovina et al.

(2015) [27]

176

Inoperable stage IIB/III

Not performed

Not performed

SUV of RLNs

Not associated with OS

Ohri et al. (2016) [25]

201

Inoperable stage IIB/III

MTV, SUVmax

Not performed

Not performed

Median OS for patients with pretreatment-MV < 93.3 cm3 22.6 vs. 20 months (p < 0.001)

Bazan et al. (2017) [13]

230

Inoperable stage IIB/III

MTV

Not performed

Not performed

Median OS for patients with pretreatment MTV > 32 cm3 14.8 vs. 29.7 months (p < 0.001)

Ohri et al. (2017) [26]

89

Inoperable stage III

MTV

Not performed

MTV

A 30-month cumulative incidence rate of 23% for lesions above 25 cm3 compared with 4% for lesions below 25 cm3 (p = 0.008)

Current study

65

Inoperable stage III

PT-MV

PT-MV

PT-MV

Median OS for patients with pre-treatment PT-MV < 63 cm3 26 vs. 11 months (p < 0.001), median OS for patients with post-treatment PTV-MV < 25 cm3 23 vs. 9 months (p < 0.001)

CT computed tomography, PET positron emission tomography, SUV standardized uptake value, TLG total lesion glycolysis, MV metabolic volume, MTV metabolic tumor volume, RLNs regional lymph nodes

We apologize for any inconvenience caused.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Olarn Roengvoraphoj
    • 1
  • Cherylina Wijaya
    • 2
  • Chukwuka Eze
    • 1
  • Minglun Li
    • 1
  • Maurice Dantes
    • 1
  • Julian Taugner
    • 1
  • Amanda Tufman
    • 3
    • 4
  • Rudolf Maria Huber
    • 3
    • 4
  • Claus Belka
    • 1
    • 4
  • Farkhad Manapov
    • 1
    • 4
  1. 1.Department of Radiation Oncology, University HospitalLMU MunichMunichGermany
  2. 2.Department of PulmonologyAsklepios Fachkliniken München-GautingMunichGermany
  3. 3.Respiratory Medicine and Thoracic Oncology, Internal Medicine VLudwig-Maximilians-University of Munich and Thoracic Oncology Centre MunichMunichGermany
  4. 4.members of the German Centre for Lung Research (DZL CPC-M)GiessenGermany

Personalised recommendations